Summary Immune checkpoint blockade has transformed cancer therapy, but durable benefit is limited to a subset of patients and can be accompanied by immune-related adverse events. This Review evaluates inhibitory receptor profiles as candidate biomarkers for predicting both antitumor benefit and immune toxicity. We exam...
Xiao-Dong Wang, Di Xiong, Bing-Chen Duan et al.· iScience· 0 citations
Radiotherapy can convert local tumor injury into systemic antitumor immunity, but this effect depends less on the nominal mode of cell death than on the tissue state that follows irradiation. This narrative review reframes radiation-induced regulated cell death around four functional outputs: antigen preservation, prod...
Xiao-Dong Wang, Wei-Yi Gao, Qian-Qian Wang et al.· Cancer Letters· 0 citations
A biomarker-guided strategy that combines tumor visibility, immune-cell state, spatial architecture, systemic inflammation, and early treatment dynamics to identify the dominant resistance topology is proposed to restore productive immune pressure while limiting compensatory escape and toxicity.
It is proposed that future progress will depend on ecosystem-matched combinations guided by spatial biomarkers, on-treatment pharmacodynamics, and adaptive trial designs capable of linking mechanism to clinical decision-making.
